CN104940770B - A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis - Google Patents
A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis Download PDFInfo
- Publication number
- CN104940770B CN104940770B CN201510447729.8A CN201510447729A CN104940770B CN 104940770 B CN104940770 B CN 104940770B CN 201510447729 A CN201510447729 A CN 201510447729A CN 104940770 B CN104940770 B CN 104940770B
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- superficial gastritis
- medicinal composition
- tibetan medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Tibetan medicinal composition for being used to treat chronic superficial gastritis, active component forms made of the bulk drug of following parts by weight：50 parts of Tibet inula root, 200 parts of rheum officinale, 100 parts of kaempferia galamga, forge 250 parts of Gypsum, 150 parts of myrobalan.Described active component can be the fine powder after the bulk drug crushes；Can also be by after the Tibet inula root in the bulk drug, rheum officinale, kaempferia galamga, myrobalan's traditional extraction, drying, Gypsum is forged in addition, is ground into fine powder and is made.By showing the pharmacodynamics test of rat chronic superficial gastritis, after the Tibetan medicinal composition using the present invention, body weight significantly increases；Stomach lining inflammation can effectively be suppressed and reduce stomach lining pathologic damage, promote stomach blood flow, reduce serum GAS content; suppress G cell activations; gastric acid secretion, protection mucosal lesion position are reduced, this prescription has good effect for treating chronic superficial gastritis.
Description
Technical field
The present invention relates to a kind of Tibetan medicine prescription for treating superficial gastritis, belong to Tibetan medicine field.
Background technology
Chronic superficial gastritis (CSG) is the gastric mucosal lesions as caused by various different pathogenies, thin to be starched in gastric mucosa layer
The chronic inflammatory cell infiltration such as born of the same parents and lymphocyte is main performance, and is sexually revised with the atrophy of stomach lining, is clinically most
Common chronic gastropathy, the treatment method of special efficacy is there is no at present.
It is Tibetanmedicine classics proved recipe that Liuwei Anxiao, which dissipates, the history of existing more than 100 years, record at present in《Chinese Pharmacopoeia》2010
Year version one.It is formulated composition and (forges) 250g, myrobalan 150g, alkali for Tibet inula root 50g, rheum officinale 200g, kaempferia galamga 100g, Gypsum
Flower 300g, it is mainly used in stomachache turgor caused by incoordination between the spleen and the stomach, internal stagnation, indigestion, constipation, dysmenorrhoea.Contain based on alkali flower
The branched crystallization of sodium carbonate, can disappear stagnant, for stomach cold, indigestion.Liuwei Anxiao dissipates alkali in side and spends dosage very big, based on
Medicine.
The content of the invention
It is an object of the present invention to provide a kind of Tibetan medicinal composition for being used to treat chronic superficial gastritis.
Tibetan medicinal composition of the present invention, active component forms made of the bulk drug of following parts by weight：Tibet inula root
50 parts, 200 parts of rheum officinale, 100 parts of kaempferia galamga, forge 250 parts of Gypsum, 150 parts of myrobalan.
The active component of the present invention can be the fine powder after the bulk drug crushes；Can also be by the Tibetan in the bulk drug
After the banksia rose, rheum officinale, kaempferia galamga, myrobalan are using conventional method extraction, drying, Gypsum is forged in addition, is ground into fine powder jointly and is made.
It is a further object to provide the Tibetan medicinal composition in treatment chronic superficial gastritis medicine is prepared
Application.Can pharmacy allows when addition prepares different dosage forms in the active component of described Tibetan medicinal composition various routines
Auxiliary material, such as disintegrant, lubricant, adhesive are prepared into any conventional peroral dosage form with the method for Chinese medicinal of routine,
Such as powder, pill, capsule, granule, tablet.
Beneficial effects of the present invention：
By showing the pharmacodynamics test of rat chronic superficial gastritis, rat model is combined using the Tibetan medicine of the present invention
After thing, body weight shows a marked increase, with normal group indifference (P ＞ 0.05)；Stomach lining inflammation can effectively be suppressed and reduce stomach and stick
Film pathologic damage, promote stomach blood flow, reduce serum GAS content, suppress G cell activations, so as to reduce hydrochloric acid in gastric juice point
Secrete, protection mucosal lesion position, this prescription has good effect for treating chronic superficial gastritis.
Brief description of the drawings
Fig. 1 is normal rat stomach lining electron-microscope scanning figure；
Fig. 2 is CSG rat model stomach lining electron-microscope scanning figures；
Fig. 3 is that Wei-Mei-Su tablet treats CSG gastric mucosa electron-microscope scanning figures；
Fig. 4 is that Liuwei Anxiao dissipates treatment CSG gastric mucosa electron-microscope scanning figures；
Fig. 5 is 1 group for the treatment of CSG gastric mucosa electron-microscope scanning figure of novel composing prescription；
Fig. 6 is 2 groups for the treatment of CSG gastric mucosa electron-microscope scanning figures of novel composing prescription.
Embodiment
Embodiment 1
Take Tibet inula root 50g, rheum officinale 200g, kaempferia galamga 100g, Gypsum (to forge) 250g, myrobalan 150g, be ground into jointly thin
Powder, mix, packing, produce powder 1.
Embodiment 2
Tibet inula root 50g, rheum officinale 200g, kaempferia galamga 100g, Gypsum (forge) 250g, myrobalan 150g.The taste of the above 5, except north is cold
Water stone (forging) outside, the taste of remaining Tibet inula root etc. 4, adds water to cook 2 times, 2 hours for the first time, and second 1 hour, filtration, filtrate merged,
Thick paste is condensed into, adds appropriate amount of starch, is mixed, is dried, Gypsum (forging) is added, is ground into fine powder jointly, is mixed, packing,
Produce powder 2.
Experimental example, the pharmacodynamics test to rat chronic superficial gastritis
1 test material
1.1 animal
SD rats, body weight 200 ± 20g, SPF level, male and female half and half, 6 week old, by Shandong Traditional Chinese Medicine University's Experimental Animal Center
There is provided.
1.2 medicines and reagent
Wei-Mei-Su tablet (lot number：141009, Beihai Yangguang Pharmaceutical Co., Ltd.)；Rat gastrin (GAS) kit (batch
Number：201209), rat motilin (MTL) elisa kit (lot numbers：201209, Bio-swamp companies)；Pepsin is tested
Box (lot number：20121011, Bioengineering Research Institute is built up in Nanjing)；Chloraldurate (lot number：20101002, Tianjin Ke Miou
Chemical reagent development centre)；2,4,6- picric acid (lot numbers：20110904, Guangzhou Chemical Reagent Factory)；PBS reagent
Wrap (lot number：AR0030, doctor's moral bioengineering Co., Ltd).Each medicinal material provides by Jin He Tibetan medicines limited company.Its
Its reagent is that analysis is pure or pure provisional configuration is analyzed in use.
1.3 key instrument
UV-2450 type Shimadzu ultraviolet specrophotometers；Shimadzu AUW220D electronic balances；YP10002 toy electronic scales
(Shanghai You Ke instrument and meters Co., Ltd)；HC3018R high speed freezing centrifuges (Anhui Zhong Ke scientific instrument Co., Ltd)；
TDL-40B low speed large capacity centrifuges (Anting Scientific Instrument Factory, Shanghai)；The laser doppler flowmetries of ML 191,
The Physiological Signal Acquiring Systems of Powerlab16/30 16 (Australian Adinstruments companies)；6219 acidometers (on
Extra large Ren Shi Electronics Co., Ltd.s)；The histopathologies of EG 1160 embedding instrument, (German Leica is public for RM2135 tissue pathological slices machine
Department)；ECLIPSE Ti-S electron microscopes (Japanese Nikon companies)；BH-2 light microscopes (Japanese Olympus companies)；S-
3000N ESEMs (Japanese Hitachi companies)；IMARK ELIASAs (Bio-Rad companies of the U.S.).
2 test methods
2.1 rat chronic superficial gastritis (CSG) model copies
SPF level SD rats, 200 ± 20g, male and female half and half.After adaptability is raised 7 days, unqualified animal is rejected, is randomly divided into
Normal group, model copy group.Daily 0.02% ammoniacal liquor of model copy group is freely drunk, while coordinates irregular diet (to prohibit within 1 day
Food, is satiated with food for 2 days) replicate chronic superficial gastritis model.Randomly selected greatly in 60d, 80d, l00d after modeling starts
Mouse carries out gastric tissue pathology detection, is replicated successfully with there is the pathological change decision model of CSG gastric tissues, 100 after modeling
The success of its model copy.
2.2 packets and administration model copy group rat are grouped at random：1 group of novel composing prescription (the gained powder 1 of embodiment 1)；New group
Side's 2 groups (gained powders 2 of embodiment 2)；Liuwei Anxiao dissipates group；Positive drug Wei-Mei-Su tablet control group；Model control group, and and just
Normal control group together enters experiment.Normal group and the daily gavage of model control group and the isometric water of medicine group, other components
Other gavage relative medicine solution, continuous gavage 30 days, once a day, 2.0ml/100g body weight.Dosage is respectively：
Wei-Mei-Su tablet control group：0.035g/100g
2 groups of 1 group of novel composing prescription and novel composing prescription：0.09g crude drugs/100g
Liuwei Anxiao dissipates group：0.09g/100g
2.3 statistics and analysis
As a result withRepresent, data are analyzed using SPSS17.0 softwares.
3 evaluation indexes
3.1 the general physiological status of rat and changes of weight observation
During administration, rat diet, flooded condition and the general physiological status of animal are observed daily, recording exceptional performance, is surveyed
15,30 days rat body weights after fixed administration.Had a net increase of with body weight value added for evaluation index, calculated as follows：
Body weight net increase (body weight before body weight-administration after Δ g)=administration.
3.2 mucosal lesion situations are observed
Intestinal tube is ligatured under pyloric ring at 0.3cm, l0mlpH 7.2-7.6 PBS solution is injected from esophagus to gastral cavity, immediately
Esophagus ligatures, and takes out stomach and is soaked in frozen water.Exposed gastral cavity is cut off along greater curvature after 15min, is exenterated, record stomach sticks
Membrane damage situation.Mucosal lesion rate (%)=mucosal lesion area/stomach lining gross area * 100%
3.3 gastric tissue pathologic findings
After experimental period terminates, rat is put to death, gastric tissue is fixed with 10% formalin and carries out routine paraffin wax embedding, cut
Piece, dyed through HE, using chronic inflammation degree, activity level, deformation and interstitial congestion and edema degree three as Score index,
Each is normal (-), slight (+), moderate (++), severe (+++), finally using both body of stomach and pyloric part score sum as
Inflammatory appraisal result：
Normal 0 point；Slight 1-4 points；5-8 points of moderate；More than severe 9 is divided
3.4 stomach lining scanning electron microscopic observations
0.5cm is taken after being cut off along greater curvature2Pyloric part, pH7.2-7.6PBS buffer salt solutions vibration washing 3 times, every time
3min, it is put into immediately in 2.5% glutaraldehyde solution, 4 DEG C of fixed more than 4h.Then, gastric tissue gradient alcohol dehydration, acetic acid isoamyl
Ester interchange, it is dried in vacuo, metal spraying, is observed under S-3000N ESEMs, records 500,1000,2000 times of lower stomach linings and epithelium
Cellular morphology.
3.5 gastric epithelial cells functional evaluation
After gastric tissue paraffin section, dyed using A Lixinlan-Glycoprotein binding method (AB-PAS), high-power biological microscope
Under (400 ×), record pyloric part and 3, each area of pyloric part independent observation face (each sightingpiston at least more than 6 continuous linears
The superficial epithelial cells of arrangement).Microscope and software observation epithelial cell mucin secretor state, wherein acid mucus is in blueness
(IPP softwares are with red-label), Combination mucus are in pale red (IPP in aubergine (IPP softwares yellow flag) and epithelial cell
Software is with Green Marker).Epithelial cell mucin index and acid mucoprotein index are calculated as follows：
Epithelial cell mucin index (%)=(acid mucus area+mixing mucus area/epithelial cell area) ×
100%
Acid mucoprotein index (%)=(acid mucus area/epithelial cell area) × 100%
3.6 pepsin activities and pH measure
Rat anaesthetizes layback pose gesture with 10% chloraldurate (0.35ml/100g), and padded head is higher than stomach position, to imprison
Ligatured at the lower 0.3cm of door.After 5 hours, cut off at ligation and collect 5 hours gastric juice, 4000rpm/min centrifugations with 10ml centrifuge tubes
15min, Aspirate supernatant measurement volume are simultaneously transferred to 2.0mlEP pipes, centrifuge 10min, take supernatant to be determined by kit specification
Pepsin activity, acidometer and accurate pH test paper measure pH value.
3.7 stomach microcirculatory blood flows determine
Rat anesthesia layback pose gesture, a left side finally helps 0.3-0.5cm hairs under bone, cuts off skin and muscle layer, cut short stomach
Small crook mesentery fully exposes body of stomach, with laser doppler flowmetry pin probes measure stomach between esophageal arteries,inferior 3-4
Body portion microcirculatory blood flow (during test, physiological saline gauze keeps body of stomach moistening), (is avoided in body of stomach and pyloric part intersection
Main artery, vein), determine pyloric part CBF.
3.8 gastrins (GAS), motilin (MTL) assay
After rat anesthesia, abdominal aortic blood, 3500rmp/min centrifugation 15min, by kit (elisa methods) operation side
GAS and MTL contents in method measure serum.
4 results and analysis
The general physiological status of 4.1 dosage period rats, changes of body mass
During experimental animal is administered, no food refusal phenomenon, the state of mind is normal, body atremia, writhing, sticks up phenomena such as tail,
Rat nose, eye, oral cavity secretion without exception, eupnea；Model control group hair is partially yellow.It is big with model group after administration 15 days
Mouse body weight is compared, and normal group, 2 groups of novel composing prescription and Wei-Mei-Su tablet group dramatically increase, and Liuwei Anxiao dissipates group, 1 group of novel composing prescription
Without significant difference compared with model group；After administration 30 days, each group rat body weight has growth, compared with model control group, new group
2 groups of side, Wei-Mei-Su tablet group have pole significant difference (P ＜ 0.01), and there were significant differences for 1 group of novel composing prescription, and Liuwei Anxiao dissipates group indifference
It is different；Compared with dissipating group with Liuwei Anxiao, 2 groups of novel composing prescription has pole significant difference.Show that Liuwei Anxiao dissipates influences on the body weight of CSG rats
Unobvious, and 1 group of novel composing prescription is effective but effect is slower, 2 groups of effects of novel composing prescription are faster and better, similar with Wei-Mei-Su tablet effect.Knot
Fruit is shown in Table 1.
Influence of the table 1 to CSG rat body weights
Compared with Normal group, #P<0.05, ##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and compares Δ P<0.05, Δ Δ P<0.01.
4.2 pairs of CSG gastric mucosas damage observations
Rat stomach dissects gross examination of skeletal muscle, rats in normal control group stomach lining smooth pliable, in Chinese red；Model control group is big
Mouse mucous membrane congestion and edema, it is dispersed in point-like, spot or strip bleeding and erosion, it is seen that remote hemorrhage point and fresh blutpunkte.IPP
Software analysis understands that chronic superficial gastritis model control group animal bleeds point or spot area increase, and mucosa injury rate is high.New group
After 1,2 group of side and Wei-Mei-Su tablet group are administered 30 days, the relatively smooth softness of gastral cavity mucous membrane, in pale red, blutpunkte or spot area subtract
Few, mucosa injury rate is compared with model control group, inequality heteropole its notable (P ＜ 0.01), and Liuwei Anxiao dissipates group and also had significantly
Improvement result (P ＜ 0.05).It the results are shown in Table 2.
Influence of the table 2 to CSG rat mucosa injuries
| Group | Number of animals (n) | Mucosa injury rate (%) |
| Normal group | 10 | 24.5 |
| Model control group | 10 | 90.8## |
| Wei-Mei-Su tablet group | 10 | 32.7** |
| Liuwei Anxiao dissipates group | 10 | 69.4* |
| 1 group of novel composing prescription | 10 | 34.7**Δ |
| 2 groups of novel composing prescription | 10 | 35.8**Δ |
Compared with Normal group,#P<0.05,##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and comparedΔP<0.05,ΔΔP<0.01。
4.3 pairs of CSG rat stomach Histopathology Effects
Normal group stomach lining glandular tube marshalling, size shape is consistent, and in single-column shape, stomach glands arrangement is close whole
Together, parietal cell, chief cell boundary clear, have no inflammatory cell infiltration in lamina propria, submucosa without or slightly slight oedema；Model
Control group gastric gland pipe is disorderly or density is uneven, and mucous layer is in congested oedema, it is seen that a large amount of epithelial cell necrosis come off, under mucous membrane
Layer oedema is obvious, while mucosa lamina propria and muscularis mucosae is thinning, disorderly, lower edge defect, submucosa inflammatory cell it is common and to
Mucous layer migrates, mucosa lamina propria occur inflammatory cell infiltration (based on lymphocyte and eosinophil, a small amount of neutral grain
Cell), degree is based on slight.After administration 30 days, novel composing prescription group stomach lining lamina propria inflammatory cell number is reduced, gastric gland arrangement
Slightly neat smooth and glandular tube construction is gradually regular.As a result show, 1,2 group of novel composing prescription changes to chronic superficial gastritis gastric tissue pathology
Change significantly inhibits effect.Compared with dissipating group with model control group and Liuwei Anxiao, the gastric tissue pathology of novel composing prescription group rat are commented
Dividing significantly reduces (P<0.05).Using rank test, 3 are the results are shown in Table.
Influence of the table 3 to CSG rat stomach histopathologies
Compared with Normal group,#P<0.05,##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and comparedΔP<0.05,ΔΔP<0.01。
4.4 pairs of CSG gastric mucosa scanning electron microscope analysis results
Rats in normal control group stomach lining is separated into many area gastricas by crisscross ditch, and boundary is clear, in mesh
Shape, there are many foveolae gastricaes (gastric gland opening) in area gastrica, foveolae gastricae is in gyrus shape, and wall liner has circular or oval epithelial cell,
Volume is basically identical, and queueing discipline；CSG rat model stomach lining structures are flat, and area gastrica boundary is unclear, small recess deformation,
It is not of uniform size, it is uneven, skewness, epithelial cell is flat and has diabrosis, erosion and comes off, and forms microulceration and gruel
Rotten face, and extruding, destroy adjacent cells to external expansion centered on field of bursting, cause cell shape and irregular arrangement.In addition,
The visible red blood cell of rat model stomach lining, inflammatory cell ooze out, swell pleat height fluctuating, the not first-class mucosa injury table of width
It is existing；1,2 group of novel composing prescription, the crisscross ditch of stomach lining stomach is deepened, dike shape protuberance is reduced, and foveolae gastricae arrangement is gradually regular, stomach
Cell boundary is clear, mucosal epithelial cells swelling shape, adhesion, but structure, form are normal, and necrosis comes off reduction, mucous membrane table
Present rotten area and be obviously reduced in face.(see Fig. 1-Fig. 6).
The influence of 4.5 pairs of CSG gastric mucosa epithelial cells functions
As a result the blue dye of visible Normal group outermost layer acidity slime layer is complete, continuous, resists acidic gastric juice to mucous membrane
The damage of lamina propria；Because acid slime layer is destroyed, blued area is reduced and discontinuous model control group.Mucous membrane screen after administration
Barrier integrality is gradually recovered, and compared with 1 group of novel composing prescription dissipates group with model control group and Liuwei Anxiao, epithelial cells mucoprotein refers to
Number and acid mucoprotein index dramatically increase；There were significant differences compared with model control group for 2 groups of novel composing prescription, dissipates group with Liuwei Anxiao
Comparing difference is not notable.It the results are shown in Table 4.
The influence that table 4 is secreted to CSG gastric mucosas epithelial cell mucin
Compared with Normal group,#P<0.05,##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and comparedΔP<0.05,ΔΔP<0.01。
The influence of 4.6 pairs of CSG rat stomach secreting functions
Test result indicates that compared with model group, 1,2 group of rat gastric secretion of novel composing prescription has certain reduce but without notable
Sex differernce；The pH value of gastric juice has rise trend but there was no significant difference, prompts novel composing prescription 1 and 2 to have the gastric juice acid that has a certain upgrade
Degree, the effect trend for suppressing CSG rat gastric juice excessive secretions；Determination of peptic activity result shows, with model control group and
Liuwei Anxiao dissipates group and compared, and the abnormal activity (p ＜ 0.05) that 1,2 group of novel composing prescription can significantly reduce pepsin, prompts it to have
Significantly mitigate erosive damage of the pepsin to stomach lining.Liuwei Anxiao, which dissipates, also certain effect to These parameters but effect is simultaneously
It is not notable.It the results are shown in Table 5
Influence of the table 5 to CSG rat stomach secreting functions
Compared with Normal group,#P<0.05,##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and comparedΔP<0.05,ΔΔP<0.01。
The influence of 4.7 pairs of CSG rat stomach microcirculatory blood flows
Compared with Normal group, model control group rat body of stomach, pyloric part stomach microcirculatory blood flow significantly reduce；Give
After medicine 30 days, compared with model control group, 1,2 group of microcirculatory blood flow of novel composing prescription dramatically increases (p ＜ 0.05), wherein new group
1 group of side dramatically increases (p ＜ 0.05) compared with dissipating group with Liuwei Anxiao.1 group of novel composing prescription dissipates group comparing difference not with Liuwei Anxiao
Significantly.It the results are shown in Table 6.
Influence of the table 6 to CSG rat stomach blood flows
Compared with Normal group,#P<0.05,##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and comparedΔP<0.05,ΔΔP<0.01。
The horizontal influence of 4.8 pairs of CSG rats gastrins (GAS), motilin (MTL)
Test result indicates that after being administered 30 days, compared with dissipating group with model control group and Liuwei Anxiao, 1,2 group of blood of novel composing prescription
Slurry MTL content is significantly increased, and has significant difference (p ＜ 0.05)；And for serum GAS contents, 1,2 group of novel composing prescription with
Wei-Mei-Su tablet group is similar, has reduction trend but there was no significant difference, so as to reduce gastric acid secretion, protection mucosal lesion portion
Position.It the results are shown in Table 7.
The influence horizontal to CSG rats gastrin (GAS), motilin (MTL) of table 7
Compared with Normal group,#P<0.05,##P<0.01；The * P compared with model control group<0.05, * * P<0.01；With
Liuwei Anxiao dissipates group and comparedΔP<0.05,ΔΔP<0.01
In summary, novel composing prescription medicine has significantly therapeutic action, this main table of effect to chronic superficial gastritis
Suppress stomach lining inflammation now and reduce stomach lining pathologic damage, promote stomach blood flow, reduce serum GAS content,
Suppress G cell activations, so as to reduce gastric acid secretion, protection mucosal lesion position, action effect is similar with Wei-Mei-Su tablet.
Claims (5)
1. a kind of Tibetan medicinal composition for being used to treat chronic superficial gastritis, it is characterised in that by the bulk drug of following parts by weight
Manufactured active component composition：50 parts of Tibet inula root, 200 parts of rheum officinale, 100 parts of kaempferia galamga, forge 250 parts of Gypsum, 150 parts of myrobalan.
2. the Tibetan medicinal composition according to claim 1 for being used to treat chronic superficial gastritis, it is characterised in that described
Fine powder after active component is crushed by the bulk drug is made.
3. the Tibetan medicinal composition according to claim 1 for being used to treat chronic superficial gastritis, it is characterised in that described
Active component is that addition is forged after the Tibet inula root in the bulk drug, rheum officinale, kaempferia galamga, myrobalan are used conventional method extraction, dried
Gypsum, fine powder is ground into jointly and is made.
4. the Tibetan medicinal composition described in claim any one of 1-3 is preparing the application in treating chronic superficial gastritis medicine.
5. Tibetan medicinal composition according to claim 4 is preparing the application in treating chronic superficial gastritis medicine, it is special
Sign is, the various customary adjuvants that pharmacy allows are added in described Tibetan medicinal composition active component, are prepared into pharmacy
Upper acceptable powder, pill, capsule, granule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510447729.8A CN104940770B (en) | 2015-07-27 | 2015-07-27 | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510447729.8A CN104940770B (en) | 2015-07-27 | 2015-07-27 | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104940770A CN104940770A (en) | 2015-09-30 |
| CN104940770B true CN104940770B (en) | 2018-02-23 |
Family
ID=54156193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510447729.8A Active CN104940770B (en) | 2015-07-27 | 2015-07-27 | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104940770B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331054A (en) * | 2018-11-23 | 2019-02-15 | 内蒙古民族大学附属医院 | A kind of anaesthetic that treating stomach trouble and its preparation process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546133A (en) * | 2003-12-04 | 2004-11-17 | 玲 张 | Prescription and preparing process and formulation of Liuwei Nengxiao capsule |
| CN102526574A (en) * | 2011-12-28 | 2012-07-04 | 江西青春康源制药有限公司 | Traditional Chinese medicine preparation-Liuwei Anxiao Pills and preparing method thereof |
-
2015
- 2015-07-27 CN CN201510447729.8A patent/CN104940770B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546133A (en) * | 2003-12-04 | 2004-11-17 | 玲 张 | Prescription and preparing process and formulation of Liuwei Nengxiao capsule |
| CN102526574A (en) * | 2011-12-28 | 2012-07-04 | 江西青春康源制药有限公司 | Traditional Chinese medicine preparation-Liuwei Anxiao Pills and preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 六味安消胶囊治疗功能性消化不良临床观察;方英杰;《中国中西医结合学会第十三次全国消化系统疾病学术研讨会论文汇编》;20011031;176 * |
| 六味安消胶囊组方原理探讨;马学清;《中国中西医结合学会第十三次全国消化系统疾病学术研讨会论文汇编》;20011031;198-199 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104940770A (en) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN104940770B (en) | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis | |
| CN101601743B (en) | Pharmaceutical composition for treating ulcerative colitis and preparation method thereof | |
| CN109718273A (en) | Perilla leaf extract is preventing or is treating the application in Osteoarthritis | |
| CN110339232A (en) | A kind of Chinese medicine composition prevented and/or treat ischemical reperfusion injury | |
| CN101647856B (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN104127798A (en) | Application of traditional Chinese medicine composition in preparation of medicine used for inhibiting metastasis of cancer cells to peritoneum | |
| CN105056128B (en) | A kind of Chinese medicine composition and preparation method and application for treating atrophic gastritis and intestines | |
| CN111150799A (en) | Composition for preventing and treating hyperuricemia and gout as well as preparation method and application thereof | |
| CN105194225A (en) | Traditional Chinese medicine for treatment of children iron deficiency anemia | |
| CN107029084A (en) | A kind of Chinese medicine composition and its pharmaceutical preparation for treating Colon and rectum precancerous lesion and application | |
| CN114392337A (en) | Composition with auxiliary protection function on gastric mucosal injury and application thereof | |
| CN107158302A (en) | It is a kind of to be used to protect natural drug composition of gastric mucosa and preparation method thereof | |
| CN108938760A (en) | A kind of application of Chinese medicine composition in preparation treatment medicine for treating arthritis | |
| Sharma et al. | A comparative study between rubber band ligation and local application of herbal caustic compound (pratisaraneeya kshara) in management of internal haemorrhoids | |
| WO2018045959A1 (en) | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product | |
| CN107714752A (en) | Composition, its preparation method and application | |
| CN108653607B (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN110934980B (en) | Traditional Chinese medicine formula and application thereof | |
| CN104984040A (en) | Medicine for treating phthisic hemoptysis | |
| Osato | Chemotherapy of human carcinoma with citronellal and citral and their action on carcinoma tissue in its histological aspects up to healing | |
| CN106038797A (en) | Pharmaceutical composition for preventing and treating bladder cancer | |
| Turakolov | LIVER FASCIOLISIS AS A RE-EMERGENCY DISEASE | |
| CN117180321A (en) | Application of penthorum chinense pursh in preparation of medicines for treating or preventing and treating blood creatinine rising and health-care products | |
| CN104069412A (en) | Traditional Chinese medicine for preventing and treating diabetes mellitus nephrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 250101 Shandong Province Jinan Hi-tech Zone Comprehensive Bonded Zone No. 1 North Section of Gangxing No. 3 Road Jinan Yaogu R&D Platform Area No. 3 Floor 8001 Patentee after: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. Address before: 250101 room 501-506, Shun Feng Road, Ji'nan hi tech Zone, Shandong, 501-506 Patentee before: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT Co.,Ltd. |
|
| CP03 | Change of name, title or address |